Literature DB >> 25417186

Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons.

Haruhiko Nakamura1, Masayuki Takagi2.   

Abstract

In 2011, a new pathological classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. The new criteria classify adenocarcinomas into eight subtypes according to their histological features. The criteria introduce a new concept of early stage lung cancer, consisting of adenocarcinoma in situ and minimally invasive adenocarcinoma, and categorize invasive adenocarcinomas by the predominant histological pattern. In addition to morphological differences among subtypes, the classification also considers the tumor behavior based on the genetic background within each subtype. We herein review the clinical impact of this new classification for chest surgeons based on the data from several recent validation studies from various institutions.

Entities:  

Keywords:  Adenocarcinoma; Chest surgery; Lung cancer; Prognosis; Subtype

Mesh:

Year:  2014        PMID: 25417186     DOI: 10.1007/s00595-014-1089-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  69 in total

1.  Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification.

Authors:  Arne Warth; Judith Cortis; Ludger Fink; Annette Fisseler-Eckhoff; Helene Geddert; Thomas Hager; Klaus Junker; Gian Kayser; Julia Kitz; Florian Länger; Alicia Morresi-Hauf; German Ott; Iver Petersen; Albrecht Stenzinger; Alex Soltermann; Saskia Ting; Verena Tischler; Ekkehard Vollmer; Philipp A Schnabel; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-06-23       Impact factor: 4.064

2.  Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification.

Authors:  T Honda; T Kondo; S Murakami; H Saito; F Oshita; H Ito; M Tsuboi; H Nakayama; T Yokose; Y Kameda; T Isobe; K Yamada
Journal:  Clin Radiol       Date:  2012-11-10       Impact factor: 2.350

3.  Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience.

Authors:  Junji Yoshida; Kanji Nagai; Tomoyuki Yokose; Mitsuyo Nishimura; Ryutaro Kakinuma; Hironobu Ohmatsu; Yutaka Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  2005-05       Impact factor: 5.209

4.  Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor.

Authors:  Kunio Araki; Yoshiteru Kidokoro; Keiko Hosoya; Makoto Wakahara; Yuki Matsuoka; Yuzo Takagi; Tomohiro Haruki; Ken Miwa; Yuji Taniguchi; Satoshi Horie; Hiroshige Nakamura
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

5.  Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Authors:  Hang Li; Yunjian Pan; Yuan Li; Chenguang Li; Rui Wang; Haichuan Hu; Yang Zhang; Ting Ye; Lei Wang; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Lung Cancer       Date:  2012-10-23       Impact factor: 5.705

Review 6.  Overview and strategic management of subsolid pulmonary nodules.

Authors:  Myrna C B Godoy; David P Naidich
Journal:  J Thorac Imaging       Date:  2012-07       Impact factor: 3.000

7.  Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection.

Authors:  Haruhiko Nakamura; Hisashi Saji; Akihiko Ogata; Takamoto Saijo; Shinya Okada; Harubumi Kato
Journal:  Lung Cancer       Date:  2004-04       Impact factor: 5.705

Review 8.  Worldwide trend of increasing primary adenocarcinoma of the lung.

Authors:  Haruhiko Nakamura; Hisashi Saji
Journal:  Surg Today       Date:  2013-06-11       Impact factor: 2.549

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

Review 10.  The evolving genomic classification of lung cancer.

Authors:  David S Shames; Ignacio I Wistuba
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

View more
  6 in total

1.  Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

Authors:  Alfonso Fiorelli; Francesco Paolo Caronia; Niccolò Daddi; Domenico Loizzi; Luca Ampollini; Nicoletta Ardò; Luigi Ventura; Paolo Carbognani; Rossella Potenza; Francesco Ardissone; Francesco Sollitto; Sandro Mattioli; Francesco Puma; Mario Santini; Mark Ragusa
Journal:  Surg Today       Date:  2016-04-16       Impact factor: 2.549

2.  A new minimally invasive technique of combined chest wall resection for lung cancer.

Authors:  Takeshi Kawaguchi; Takashi Tojo; Norikazu Kawai; Takashi Watanabe; Motoaki Yasukawa; Shigeki Taniguchi
Journal:  Surg Today       Date:  2016-02-09       Impact factor: 2.549

3.  Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?

Authors:  Noriyoshi Sawabata; Soichiro Funaki; Takeru Hyakutake; Yasushi Shintani; Ayako Fujiwara; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-03-07       Impact factor: 2.549

4.  Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.

Authors:  Jingyuan Li; Xingyuan Liu; Zan Cui; Guanying Han
Journal:  Med Sci Monit       Date:  2020-06-24

5.  Validation of stage groupings in the eighth edition of the tumor node metastasis classification for lung adenocarcinoma.

Authors:  Wenguan Yu; Qingchun Zhao; Chunqiu Xia; Ming Dong; Jinghao Liu; Xin Li; Honglin Zhao; Gang Chen; Hongyu Liu; Jun Chen
Journal:  Thorac Cancer       Date:  2019-01-16       Impact factor: 3.500

6.  The Characteristics and Nomogram for Primary Lung Papillary Adenocarcinoma.

Authors:  Yuqian Zhang; Hui Xie; Ziying Zhang; Pengfei Zhang; Peng Chen; Xiang Wang
Journal:  Open Med (Wars)       Date:  2020-02-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.